
Commentary|Articles|March 31, 2026
Rising Rates, Screening Gaps, and Emerging Therapeutic Targets in CRC: Your Key Clinical Questions Answered
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Nicole Canfora Lupo
Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.
Advertisement
Advertisement
During colorectal cancer (CRC) awareness month, OncLive® sat down with Jeremy Kortmansky, MD, to discuss frequently asked questions about the complexities of CRC management and the rising incidence of CRC in young adults. The following FAQ, adapted from the conversation, provides clinical insights into potential risk factors for CRC in young adults, gaps in screening and early symptom identification contributing to this phenomenon, and the evolving landscape of molecularly targeted therapies in the space.
Related to this article

Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.

Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.

Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.

Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Advertisement
Advertisement


